This is a prospective study of expression profiling-based assessment of the efficacy of neoadjuvant therapy for rectal cancer.
Age ≥18 years, male or infertile female
Patients with rectal adenocarcinoma diagnosed by colonoscopic biopsy
Neoadjuvant therapy according to guideline recommendations
Endoscopic biopsy with access to biopsy tissue for subsequent RNA-seq testing
Samples are not collected, stored, or processed in accordance with specified requirements
Sample does not meet the requirements for subsequent RNA-seq testing
Cases enrolled with a subsequent diagnosis other than rectal adenocarcinoma.
The patient refuses or is unable to complete the entire neoadjuvant treatment